Efpeglenatide and Heart and Kidney Outcomes in Type 2 Diabetes. Reply

N Engl J Med. 2021 Nov 25;385(22):2107. doi: 10.1056/NEJMc2115776.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Diabetes Mellitus, Type 2* / complications
  • Diabetes Mellitus, Type 2* / drug therapy
  • Glycated Hemoglobin
  • Humans
  • Hypoglycemic Agents / adverse effects
  • Kidney
  • Proline

Substances

  • Glycated Hemoglobin A
  • Hypoglycemic Agents
  • efpeglenatide
  • Proline